Afasci Research Laboratories
- Biotech or pharma, therapeutic R&D
AfaSci is a clinical stage biotech based in the San Francisco Bay Area specializing in the development of CNS targeting small molecules. Our lead asset, AFA-281, has successfully completed Phase 1 SAD/MAD and is ready to enter Phase 2 trials in neuropathic pain or epilepsy. AfaSci has a robust pipeline of assets with two other novel small molecules currently in IND enabling studies. AfaSci has raised $25m in nondilutive funding through NIH grant mechanisms and is currently seeking $30m in Series A financing. We are looking to meet with investors and to identify potential development partners and/or out-licensing opportunities.
PLEASE NOTE: We will not be taking meetings with service providers of any sort including CROs, CDMOs, or consulting groups.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}